Perrigo Company plc Securities Lawsuit Investigation

Shamis & Gentile P.A., a law firm that advocates for investors who are victims of securities fraud, is investigating potential claims against Perrigo Company plc (PRGO).

If you purchased or otherwise acquired Perrigo Company plc securities between November 2022 and November 2025, you may be eligible to join this securities investigation and seek compensation.

About Perrigo

Perrigo is a global consumer self-care company that produces and markets over-the-counter health and wellness products. The company’s operations include nutrition, where its infant formula segment has played a key strategic role in recent years.

Potential Concerns Under Investigation

Attorneys are reviewing whether Perrigo and certain executives may have made false or misleading statements or failed to disclose material information regarding the performance, safety, and regulatory compliance of its infant formula business.

The investigation covers a series of events beginning with Perrigo’s November 2022 acquisition of Nestlé’s Gateway plant and the Good Start brand, a $170 million transaction the company described as a long-term investment to expand U.S. manufacturing and strengthen supply-chain reliability.

Less than a year later, on August 30, 2023, the U.S. Food and Drug Administration issued a warning letter to the Wisconsin facility acquired in that deal, citing compliance concerns later noted in Perrigo’s regulatory filings.

In August 2024, Perrigo filed an 8-K reporting a voluntary recall of approximately 16,500 cans of infant formula, which may have reflected ongoing quality or regulatory challenges linked to the same facility. Despite these developments, public communications during this period appeared focused on maintaining investor confidence in the company’s infant formula operations.

That messaging was revisited on November 5, 2025, when Perrigo announced a strategic review of its infant formula business and a reassessment of a $240 million investment. The company also revised its full-year 2025 earnings guidance from $2.90 to $3.10 per share down to $2.70 to $2.80 per share.

Following the disclosure, Perrigo’s stock plunged about 25%, falling from approximately $20.19 at close on November 4, 2025, to $15.10 when markets closed on November 5, 2025, resulting in significant losses for investors.

Lawyers are examining whether Perrigo’s prior statements about the safety, performance, and outlook of its infant formula division adequately reflected known operational risks, regulatory challenges, and internal assessments before these issues became public.

Your Rights and Next Steps

This is an ongoing investigation and not a filed lawsuit. Investors who purchased or otherwise acquired Perrigo securities between November 2022 and November 2025 and suffered losses may have legal rights. If evidence shows that investors were misled, the case could lead to a class action lawsuit to recover damages for affected shareholders.

Lawyers are available to help investors review their options and determine whether they qualify to participate. There is no cost or obligation to join the investigation, and participation is confidential.

You May Be Entitled to Compensation

Securities investigations are time-sensitive, and acting promptly can help preserve your rights. If you purchased or otherwise acquired Perrigo securities during the relevant period, you may be eligible to seek compensation for your losses.

To learn more and take the next step, complete the form below to join the investigation.